Actively Recruiting
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Led by Sahlgrenska University Hospital · Updated on 2026-05-13
20
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
CONDITIONS
Official Title
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Insulinoma verified by pathology (often from EUS-FNB-sampling)
You will not qualify if you...
- Patients unwilling to participate
- Patients unable to understand and obtain written informed consent
- Severe comorbidity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sahlgrenska Univeristy Hospital
Gothenburg, Sweden
Actively Recruiting
Research Team
P
Per Hedenström, Associate Professor
CONTACT
R
Riadh Sadik, Associate Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here